
AMEXHealthcareMedical - Devices
Latest quote
$0.3211
−$0.0004 · -0.12%
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
Regular session
$0.3211
−$0.0004 · -0.12%
Regular session · ET · Market data may be delayed.
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
Day range
Current $0.3211
52-week range
Current $0.3211
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
79
Undervalued
Sentiment
46
Mixed
Risk
57
Elevated Risk
Momentum
18
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Xtant Medical Holdings, Inc., a company based in Belgrade, Montana, specializes in the development, production, and distribution of advanced regenerative medicine products and medical devices. The firm primarily serves orthopedic and neurological surgeons both within the United States and globally. Its comprehensive product portfolio is categorized into several key areas: 1. Biomaterial Offerings: This category includes products like OsteoSponge, which provides a natural structural support for cellular growth and introduces vital bone-forming proteins to aid the healing process. OsteoSponge SC is specifically designed to repair bone defects in the subchondral area of joints. Other items are OsteoSelect DBM Putty, fostering osteoinductive bone regeneration, and OsteoSelect PLUS DBM Putty, which functions as a bone void filler and graft substitute for procedures involving the pelvis, extremities, and posterolateral spine. Additionally, the line features OsteoFactor, containing diverse proteins and peptides that facilitate bone formation and remodeling, along with OsteoWrap and OsteoVive Plus, a cellular bone matrix enriched with growth factors. 2. Allograft Technologies: Under the 3Demin brand, Xtant Medical provides a range of allografts (human bone grafts) engineered to maximize both osteoconductivity and osteoinductive capabilities. This includes specialized sports allografts used for repairing anterior and posterior cruciate ligaments, ACL reconstruction, and meniscal repairs. They also offer milled spinal allografts, where cortical bone is precisely shaped to specific dimensions, as well as traditional allografts applicable across numerous medical disciplines such such as orthopedics, neurology, podiatry, oral/maxillofacial surgery, genitourinary, and plastic/reconstructive surgery. 3. Spinal Fixation and Fusion Systems: The company furnishes a variety of sophisticated spinal devices. These include the Certex spinal fixation system, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, the Xpress minimally invasive pedicle screw system, and Fortex Pedicle screw systems. Further systems encompass Calix, for use in cervical and thoracolumbar regions, the Axle-X interspinous fusion system, Irix-C for cervical integrated fusion, and the Irix-A Lumbar integrated fusion system. The company underwent a name change in July 2015, transitioning from its former identity as Bacterin International Holdings, Inc. to Xtant Medical Holdings, Inc.
Day range
Current $0.3211
52-week range
Current $0.3211
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 133.93M USD | 117.27M USD | 91.3M USD | 57.97M USD | 55.26M USD |
| Cost of goods sold | 49.65M USD | 49.05M USD | 35.84M USD | 25.83M USD | 22.77M USD |
| Gross profit | 84.27M USD | 68.22M USD | 55.47M USD | 32.14M USD | 32.49M USD |
| Research and development | 2.1M USD | 2.39M USD | 1.34M USD | 915K USD | 870K USD |
| Selling, general, and administrative | 74.89M USD | 77.91M USD | 64.29M USD | 37.98M USD | 35.47M USD |
| Operating expenses | 76.99M USD | 80.29M USD | 65.63M USD | 38.89M USD | 36.34M USD |
| Interest income | 94K USD | — | 149K USD | 31K USD | — |
| Interest expense | 3.67M USD | 4.16M USD | 2.94M USD | 1.69M USD | 995K USD |
| Depreciation and amortization | 5.22M USD | 4.22M USD | 3.17M USD | 1.29M USD | 1.33M USD |
| Operating income | 7.28M USD | −12.07M USD | −10.16M USD | −6.76M USD | −3.85M USD |
| Net income | 4.97M USD | −16.45M USD | 660K USD | −8.49M USD | −4.85M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 14, 2018 | 1:12 | — | — |
Stock split | Jul 28, 2014 | 1:10 | — | — |
Effective Feb 14, 2018
1:12
Effective Jul 28, 2014
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.